ATTORNEY DOCKET NO. 600-69-CIP **PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	)	Examiner: Unknown
	)	
Yuan, et al.	)	Art Unit: 1614
	)	
Serial No.: 10/656,715	)	
	)	
Filed: September 5, 2003	)	
	)	
For: Compositions and Methods Using Compounds Having Cytochrome P450RAI Inhibitory Activity Co-Administered with Vitamin A	)	

INFORMATION DISCLOSURE STATEMENT
Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Certificate of Mailing

I hereby certify that this correspondence is being deposited on December 2, 2003 with the United States Postal Service First Class Mail addressed to: Mail Stop DD, Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

Toni Whyte
Toni Whyte

December 2, 2003
Date

Dear Sir:

Pursuant to 37 CFR Sections 1.97 and 1.98, and in fulfillment of the duty of candor set forth in 37 CFR Section 1.56, Applicant cites the following documents listed on Form 1449, submitted herewith. Copies of the references are enclosed.

		US-6,313,107	11/06/01	Vasudevan, et al.	
		US-6,303,785	10/06/01	Vasudevan, et al.	
		US-5,965,606	10/12/99	Teng, et al.	
		US-5,675,024	10/07/97	Teng, et al.	
		US-5,663,347	09/02/97	Chandraratna	
		US-5,045,551	09/03/91	Chandraratna	
		US-5,023,341	06/11/91	Chandraranta	
		US-5,264,578	11/23/93	Chandraranta	
		US-5,089,509	02/18/92	Chandraratna	
		US-5,134,159	07/28/92	Chandraratna	
		US-5,346,895	09/13/94	Chandraratna	
		US-5,346,915	09/13/94	Chandraratna	
		US-5,149,705	09/22/92	Chandraratna	

		US-5,399,561	03/21/95	Chandraratna	
		US-4,980,369	12/25/90	Chandraratna	
		US-4,826,984	05/02/89	Berlin, et al.	
		US-5,037,825	08/06/91	Klaus, et al.	
		US-5,466,861	11/14/95	Dawson, et al.	
		US-6,252,090	07/26/01	Vasudevan, et al.	
		US-5,455,265	10/03/95	Chandraratna	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		WO 85/00806	02/28/85	Dawson, et al.		
		WO 95/04036	02/09/95	Boehm, et al.		
		EP 0 130,795	01/09/85	Hoffman, et al.		
		DE 3316932	11/17/83	Klaus, et al.		
		DE 3708060	09/24/87	Maignan, et al.		
		WO 93/11755	06/24/93	Evans, et al.		

		ORTIZ DE MONTELLANO, Topics in Biology- The Inactivation ofr Cytochrome P450RAI, Annual Reports in Medicinal Chemistry, 1984, Chapter 20, pg. 201-210.	☐
		HANZILK, et al., Suicidal Inactivation of Cytochrome P450RAI by Cyclopropylamines-Evidence for Cation-Radical Intermediates, J. Am. Chem. Soc. 1982, 2048-2052, v.104,n.107.	☐
		WHITE, et al. Identification of the Human Cytochrome P450), P450RAI-2, which is predomantly expressed in the adult Cerebellum and is responsible for all trans retonic acid metabolism, Proc. Natl. Acad. Sci. USA, June 6, 2000, 6403-6408, v.97, n.12	☐
		EYROLLES, et al. J. Med. Chem., 1994, 1508-1507, 37	☐
		DAWSON, et al., Chemistry and Biology of Synthetic Retinoids, 1990, 324-356,CRC Press, Inc.	☐
		KUIJPERS, et al., The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin, British Journal of Dermatology, 1998, 380-389, 139	☐
		KANG, et al., liarozole Inhibits Human Epidermal Retinoid Acid 4-Hydroxylase Activity and Differntially Augments Human Skin Responses to Retinoic Acid and Retinol In Vivo, The Journal of Investigative Dermatology, August 1996, 183-187, v.107,n.2	☐
		VAN WAUWE, et. al., Liarozole, an Inhibitor of Retinoic Acid Metabolism, Exerts Retinoid-Mimetic Effects in Vivo, The Journal fo Pharmacology and Experimental Therapeutics, 1992, 773-779, v.261, n.2.	☐
		DE PORRE, et al., second Generation Retinoic Acid Metabolism Blocking Agent (Ramba) R116010: Dose Finding in Healthy Male Volunteers, University of Leuven, Belgium, pg. 30	☐
		VAN WAUWE, et al., Ketoconazole Inhibits the in Vitro and in Vivo Metabolixm of All-Trans-Retinoic Acid, The Journal of Pharmacology and Experimental Therapeutics, 1988, 718-722, v.245, n.2	☐

WHITE, et al., cDNA Cloning of Human Retinoic Acid-metabolizing Enzyme (hP450RAI) Identifies a Novel Family of Cytochromes p450 (CYP26)*, The Journal of Biological Chemistry, July 25,1997, 18538-18541, v.272, n.30.
HANZLIK, et al., Cyclopropylamines as Suicide Substrates for Cytochromes P450RAI,

Journal of Medicinal Chemistry, 1979, 759-761, v.22,n.7
BLIGH, et al., Canadian Journal of Biochemistry, 1959, 911-917, 37.
FEIGNER P.L., et al., Focus, 1989, 112.
HEYMAN, et. al., Cell, 1992, 397-406, 68.
ALLEGRETTO, et al., J. Biol. Chem. 26625-26633, 268.
MANGELSDORF, et al., Retinoids: Biology, Chemistry, Medicine, 319-349, Raven Press, Ltd., New York.
CHENG, et al., Biochemical Pharmacology, 3099-3108, v.22.

REMARKS

Submission of the foregoing document is no representation that a search was made, or if made, that it was comprehensive, or that no other documents exist which may be material to the above-identified application. Moreover, the Applicant does not concede that the foregoing document is necessarily prior art to the invention. Copies of United States Patent References are not enclosed because the undersigned attorney understands that the Examiner has access to them.

Date: December 2, 03

By: Gabor L. Szekeres

Gabor L. Szekeres
Registration No. 28,675

Law Offices of Gabor L. Szekeres
8141 E. Kaiser Boulevard, Ste. 112
Anaheim, CA 92808
Telephone: (714) 998-3295 Facsimile: (714) 998-3296

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known	
Application Number	10/656,715
Filing Date	09/05/03
First Named Inventor	YUAN, et al.
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	600-69-CIP

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-6,313,107	11/06/01	Vasudevan, et al.	
		US-6,303,785	10/06/01	Vasudevan, et al.	
		US-5,965,606	10/12/99	Teng, et al.	
		US-5,675,024	10/07/97	Teng, et al.	
		US-5,663,347	09/02/97	Chandraratna	
		US-5,045,551	09/03/91	Chandraratna	
		US-5,023,341	06/11/91	Chandraranta	
		US-5,264,578	11/23/93	Chandraranta	
		US-5,089,509	02/18/92	Chandraratna	
		US-5,134,159	07/28/92	Chandraratna	
		US-5,346,895	09/13/94	Chandraratna	
		US-5,346,915	09/13/94	Chandraratna	
		US-5,149,705	09/22/92	Chandraratna	
		US-5,399,561	03/21/95	Chandraratna	
		US-4,980,369	12/25/90	Chandraratna	
		US-4,826,984	05/02/89	Berlin, et al.	
		US-5,037,825	08/06/91	Klaus, et al.	
		US-5,466,861	11/14/95	Dawson, et al.	
		US-6,252,090	07/26/01	Vasudevan, et al.	
		US-5,455,265	10/03/95	Chandraratna	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		WO 85/00806	02/28/85	Dawson, et al.		
		WO 95/04036	02/09/95	Boehm, et al.		
		EP 0 130,795	01/09/85	Hoffman, et al.		
		DE 3316932	11/17/83	Klaus, et al.		
		DE 3708060	09/24/87	Maignan, et al.		
		WO 93/11755	06/24/93	Evans, et al.		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. any comments on the amount of time you are required complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES FOR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complet if Kn wn	
Applicant Number	10/656715
Filing Date	09/05/03
First Named Inventor	YUAN, et al.
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	600-69-CIP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
		ORTIZ DE MONTELLANO, Topics in Biology- The Inactivation ofr Cytochrome P450RAI, Annual Reports in Medicinal Chemistry, 1984, Chapter 20, pg. 201-210.	☐
		HANZILK, et al., Suicidal Inactivation of Cytochrome P450RAI by Cyclopropylamines-Evidence for Cation-Radical Intermediates, J. Am. Chem. Soc. 1982, 2048-2052, v.104,n.107.	☐
		WHITE, et al. Identification of the Human Cytochrome P450), P450RAI-2, which is predomantly expressed in the adult Cerebellum and is responsible for all trans retonic acid metabolism, Proc. Natl. Acad. Sci. USA, June 6, 2000, 6403-6408, v.97, n.12	☐
		EYROLLES, et al. J. Med. Chem., 1994, 1508-1507, 37	☐
		DAWSON, et al., Chemistry and Biology of Synthetic Retinoids, 1990, 324-356,CRC Press, Inc.	☐
		KUIJPERS, et al., The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin, British Journal of Dermatology, 1998, 380-389, 139	☐
		KANG, et al., liarozole Inhibits Human Epidermal Retinoid Acid 4-Hydroxylase Activity and Differntially Augments Human Skin Responses to Retinoic Acid and Retinol In Vivo, The Journal of Investigative Dermatology, August 1996, 183-187, v.107,n.2	☐
		VAN WAUWE, et. al., Liarozole, an Inhibitor of Retinoic Acid Metabolism, Exerts Retinoid-Mimetic Effects in Vivo, The Journal fo Pharmacology and Experimental Therapeutics, 1992, 773-779, v.261, n.2.	☐
		DE PORRE, et al., second Generation Retinoic Acid Metabolism Blocking Agent (Ramba) R116010: Dose Finding in Healthy Male Volunteers, University of Leuven, Belgium, pg. 30	☐
		VAN WAUWE, et al., Ketoconazole Inhibits the in Vitro and in Vivo Metabolixm of All-Trans-Retinoic Acid, The Journal of Pharmacology and Experimental Therapeutics, 1988, 718-722, v.245, n.2	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	3	of	3

Complet if Kn wn	
Applicant Number	**10/656,715**
Filing Date	**09/05/03**
First Named Inventor	**YUAN, et al.**
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	600-69-CIP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
		WHITE, et al., cDNA Cloning of Human Retinoic Acid-metabolizing Enzyme (hP450RAI) Identifies a Novel Family of Cytochromes p450 (CYP26)*, The Journal of Biological Chemistry, July 25,1997, 18538-18541, v.272, n.30.	☐
		HANZLIK, et al., Cyclopropylamines as Suicide Substrates for Cytochromes P450RAI, Journal of Medicinal Chemistry, 1979, 759-761, v.22,n.7	☐
		BLIGH, et al., Canadian Journal of Biochemistry, 1959, 911-917, 37.	☐
		FEIGNER P.L., et al., Focus, 1989, 112.	☐
		HEYMAN, et. al., Cell, 1992, 397-406, 68.	☐
		ALLEGRETTO, et al., J. Biol. Chem. 26625-26633, 268.	☐
		MANGELSDORF, et al., Retinoids: Biology, Chemistry, Medicine, 319-349, Raven Press, Ltd., New York.	☐
		CHENG, et al., Biochemical Pharmacology, 3099-3108, v.22.	☐
			☐
			☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.